The STEP-1 trial, one of the landmark studies for semaglutide 2.4mg, showed that participants lost approximately 9.7% of their lean mass alongside a 19.3% reduction in fat mass
Both medications target similar pathways for appetite regulation and glucose control, and combining them offers no proven additional benefit, only heightened risk
50.00 Availability: 66 in stock (can be backordered) Discount per Quantity Buy 2 and save 5% buy 3 and save 10% Description Additional information Reviews (0) A triple-agonist peptide (GIP/GLP-1/Glucagon pathways) studied extensively in metabolic and weight-regulation research models
GLP-1 is secreted by L cells in the ileum and GLP-1 receptors are found on the beta cells of the pancreas, in the intestine, and in the hypothalamus
As we navigate this transformation, one thing is clear: the future of metabolic health is being rewritten, and India has a front-row seat in shaping its destiny